SCHEMBL10201249

SCHEMBL10201249

CCc1cc(-c2sc(C(=O)Nc3ccccc3Cl)cc2[N+](=O)[O-])n(CC)n1

nearest known ligand 0.46

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
POLB P06746 2/20 0.46
USP7 Q93009 2/20 0.42
USP47 Q96K76 2/20 0.42
NPC1 O15118 3/20 0.42
RAB9A P51151 3/20 0.42
KMT2A Q03164 3/20 0.41
MEN1 O00255 2/20 0.41
MAPT P10636 2/20 0.41
ALDH1A1 P00352 2/20 0.41
LMNA P02545 2/20 0.41
HTT P42858 1/20 0.41
SMN1; SMN2 Q16637 1/20 0.41
L3MBTL1 Q9Y468 1/20 0.39
RORC P51449 1/20 0.39
STIM1 Q13586 2/20 0.39
ORAI1 Q96D31 2/20 0.39
HPGD P15428 1/20 0.39
MIF P14174 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10201248 0.89 SMN1; SMN2 (0.47) USP7USP47NPC1RAB9AKMT2A
SCHEMBL10201236 0.89 STIM1 (0.51) POLBUSP7USP47NPC1RAB9A
SCHEMBL10201258 0.85 NPC1 (0.45) NPC1RAB9AKMT2AMEN1MAPT
SCHEMBL10201261 0.85 NPC1 (0.45) NPC1RAB9AKMT2AMEN1MAPT
SCHEMBL10201247 0.83 STIM1 (0.38) POLBUSP7USP47NPC1RAB9A
SCHEMBL10201213 0.79 SMN1; SMN2 (0.45) NPC1RAB9AKMT2AMEN1MAPT
SCHEMBL10201541 0.78 POLB (0.50) POLBUSP7USP47NPC1RAB9A
SCHEMBL10201246 0.76 POLB (0.43) POLBUSP7USP47KMT2AMEN1
SCHEMBL10201259 0.76 SMN1; SMN2 (0.51) NPC1RAB9AKMT2AMEN1MAPT
SCHEMBL10201229 0.75 STIM1 (0.54) NPC1RAB9AKMT2AMAPTALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20150344469-A1 COMPOUNDS THAT MODULATE INTRACELLULAR CALCIUM AVENUE CAPITAL MANAGEMENT II, L.P. 2015-12-03 US disclosed
US-20150344469-A1 COMPOUNDS THAT MODULATE INTRACELLULAR CALCIUM AVENUE CAPITAL MANAGEMENT II, L.P. 2015-12-03 US disclosed
US-9079891-B2 Compounds that modulate intracellular calcium CALCIMEDICA, INC. (US) 2015-07-14 US disclosed
US-9079891-B2 Compounds that modulate intracellular calcium CALCIMEDICA, INC. (US) 2015-07-14 US disclosed
US-20120053210-A1 COMPOUNDS THAT MODULATE INTRACELLULAR CALCIUM CALCIMEDICA, INC. (US) 2012-03-01 US disclosed
WO-2012027710-A2 COMPOUNDS THAT MODULATE INTRACELLULAR CALCIUM CALCIMEDICA INC. (US) 2012-03-01 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150344469-A1 COMPOUNDS THAT MODULATE INTRACELLULAR CALCIUM ORAI1, SARAF, RYR2 POLB 4774/4885USP7 4337/4885USP47 3679/4885
US-20120053210-A1 COMPOUNDS THAT MODULATE INTRACELLULAR CALCIUM ORAI1, SARAF, RYR2 POLB 4774/4885USP7 4337/4885USP47 3679/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.